Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors.

MLA

Massard, C., et al. “Phase I Dose-Escalating Study of ES-285 given as a Three-Hour Intravenous Infusion Every Three Weeks in Patients with Advanced Malignant Solid Tumors.” Investigational New Drugs, vol. 30, no. 6, Dec. 2012, pp. 2318–26. EBSCOhost, https://doi.org/10.1007/s10637-011-9772-8.

APA

Massard, C., Salazar, R., Armand, J., Majem, M., Deutsch, E., García, M., Oaknin, A., Fernández-García, E., Soto, A., & Soria, J. (2012). Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors. Investigational New Drugs, 30(6), 2318–2326. https://doi.org/10.1007/s10637-011-9772-8

Chicago

Massard, C., R. Salazar, J. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin, E. Fernández-García, A. Soto, and J. Soria. 2012. “Phase I Dose-Escalating Study of ES-285 given as a Three-Hour Intravenous Infusion Every Three Weeks in Patients with Advanced Malignant Solid Tumors.” Investigational New Drugs 30 (6): 2318–26. doi:10.1007/s10637-011-9772-8.